Adamis Pharmaceuticals Corp
Company Snapshot: Adamis Pharmaceuticals Corp
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. In its specialty pharmaceutical pipeline, ADMP is developing low cost therapeutic alternatives for the treatment of anaphylaxis, asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Within the Company's biotechnology pipeline is a novel cell-based therapeutic cancer vaccine and three drug candidates for the treatment of prostate cancer.
- Nov 12 2019 Adamis Pharmaceuticals Announces Third Quarter 2019 Financial Results and Business Update
- Nov 6 2019 Adamis Pharmaceuticals Schedules Third Quarter 2019 Earnings Conference Call and Business Update
- Nov 4 2019 Adamis Pharmaceuticals Provides Regulatory Update for Its Higher Dose Naloxone Pre-Filled Syringe
- Oct 8 2019 Adamis Pharmaceuticals Announces Presentation of ZIMHI data at IHV Scientific Meeting
- Oct 1 2019 Adamis Pharmaceuticals Announces Commercial Partnership with Emerge Health for SYMJEPI® in Australia and New Zealand